Type 1 Diabetes – vTv Therapeutics TTP399-302
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Inclusion Criteria:
- Individuals ≥18 years
- Diagnosed T1DM with a minimum of 5 years since diagnosis
- Has had at least 1 hypoglycemic event of Level 2 (glucose level <54 mg/dL or <3 mmol/L, [CGM or SMBG confirmed]) or Level 3 (defined as a severe hypoglycemia with altered mental state and/or physical status requiring assistance) in the last 2 months prior to Screening
- HbA1c value of <9.5% at Screening
- Is currently on CSII (closed-loop systems are prohibited) or is on MDI for at least 6 months prior to the Screening Visit and is willing to stay on same type of insulin treatment and the current mode of insulin administration (CSII or MDI injection treatments) for the duration of the study
- Must have used a CGM device for at least 3 consecutive months prior to Screening
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
